Title : Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia.

Pub. Date : 2008 Apr 22

PMID : 18420099






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 RESULTS: Coadministered E/S with N resulted in significantly greater reductions in LDL-C, non-high-density lipoprotein cholesterol, triglycerides, apolipoprotein B, and lipid/lipoprotein ratios, compared with either agent alone (p < 0.001). Niacin apolipoprotein B Homo sapiens